Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328


Serotonin transporter inhibition and 5-HT2C receptor activation drive loss of cocaine-induced locomotor activation in DAT Val559 mice.

Stewart A, Davis GL, Gresch PJ, Katamish RM, Peart R, Rabil MJ, Gowrishankar R, Carroll FI, Hahn MK, Blakely RD.

Neuropsychopharmacology. 2019 Apr;44(5):994-1006. doi: 10.1038/s41386-018-0301-8. Epub 2018 Dec 21.


Region-Specific Regulation of Presynaptic Dopamine Homeostasis by D2 Autoreceptors Shapes the In Vivo Impact of the Neuropsychiatric Disease-Associated DAT Variant Val559.

Gowrishankar R, Gresch PJ, Davis GL, Katamish RM, Riele JR, Stewart AM, Vaughan RA, Hahn MK, Blakely RD.

J Neurosci. 2018 Jun 6;38(23):5302-5312. doi: 10.1523/JNEUROSCI.0055-18.2018. Epub 2018 May 8.


Effectiveness of Positron Emission Tomography/Computed Tomography as a Guide for Palliative Radiation Therapy for Spinal Metastases.

Almeida ND, Adams C, Davis GL, Starke RM, Buro J, Nasr N, McRae D, Cernica G, Caputy A, Hong R, Sherman J.

World Neurosurg. 2018 Jul;115:e67-e72. doi: 10.1016/j.wneu.2018.03.171. Epub 2018 Mar 31.


Functional coding variation in the presynaptic dopamine transporter associated with neuropsychiatric disorders drives enhanced motivation and context-dependent impulsivity in mice.

Davis GL, Stewart A, Stanwood GD, Gowrishankar R, Hahn MK, Blakely RD.

Behav Brain Res. 2018 Jan 30;337:61-69. doi: 10.1016/j.bbr.2017.09.043. Epub 2017 Sep 28.


From ring-in-ring to sphere-in-sphere: self-assembly of discrete 2D and 3D architectures with increasing stability.

Sun B, Wang M, Lou Z, Huang M, Xu C, Li X, Chen LJ, Yu Y, Davis GL, Xu B, Yang HB, Li X.

J Am Chem Soc. 2015 Feb 4;137(4):1556-64. doi: 10.1021/ja511443p. Epub 2015 Jan 20.


Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID).

Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, Delmée M, Fitzpatrick F, Ivanova K, Kuijper E, Macovei IS, Mentula S, Mastrantonio P, von Müller L, Oleastro M, Petinaki E, Pituch H, Norén T, Nováková E, Nyč O, Rupnik M, Schmid D, Wilcox MH.

Lancet Infect Dis. 2014 Dec;14(12):1208-19. doi: 10.1016/S1473-3099(14)70991-0. Epub 2014 Nov 7.


Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

Buti M, Flisiak R, Kao JH, Chuang WL, Streinu-Cercel A, Tabak F, Calistru P, Goeser T, Rasenack J, Horban A, Davis GL, Alberti A, Mazzella G, Pol S, Orsenigo R, Brass C.

J Viral Hepat. 2015 Jul;22(7):596-606. doi: 10.1111/jvh.12360. Epub 2014 Nov 21.


The rare DAT coding variant Val559 perturbs DA neuron function, changes behavior, and alters in vivo responses to psychostimulants.

Mergy MA, Gowrishankar R, Gresch PJ, Gantz SC, Williams J, Davis GL, Wheeler CA, Stanwood GD, Hahn MK, Blakely RD.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4779-88. doi: 10.1073/pnas.1417294111. Epub 2014 Oct 20.


New AASLD/IDSA hepatitis C virus practice recommendations: An online resource.

Davis GL.

Clin Liver Dis (Hoboken). 2014 May 27;3(5):93-95. doi: 10.1002/cld.348. eCollection 2014 May. No abstract available.


Impact of birth cohort screening for hepatitis C.

Asrani SK, Davis GL.

Curr Gastroenterol Rep. 2014 Apr;16(4):381. doi: 10.1007/s11894-014-0381-5.


Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Mergy MA, Gowrishankar R, Davis GL, Jessen TN, Wright J, Stanwood GD, Hahn MK, Blakely RD.

Neurochem Int. 2014 Jul;73:56-70. doi: 10.1016/j.neuint.2013.11.009. Epub 2013 Dec 8. Review.


Molecular assays for determining Mycobacterium leprae viability in tissues of experimentally infected mice.

Davis GL, Ray NA, Lahiri R, Gillis TP, Krahenbuhl JL, Williams DL, Adams LB.

PLoS Negl Trop Dis. 2013 Aug 22;7(8):e2404. doi: 10.1371/journal.pntd.0002404. eCollection 2013.


Hepatitis C screening: summary of recommendations from the clinical decision tool.

Hepatitis C Task Force, Boldt MD, Brill JV, Davis GL, Gordon SC, Kim AY, Kosinski LR, Levy AG, Nahass RG, Allen JI.

Gastroenterology. 2013 Nov;145(5):1146-9. doi: 10.1053/j.gastro.2013.09.007. No abstract available.


Preventing cancer: a community-based program for youths in public housing.

Strunin L, Wulach L, Yang GJ, Evans TC, Hamdan SU, Davis GL, Bowen DJ.

J Adolesc Health. 2013 May;52(5 Suppl):S83-8. doi: 10.1016/j.jadohealth.2013.01.010.


Effect of elastin digestion on the quasi-static tensile response of medial collateral ligament.

Henninger HB, Underwood CJ, Romney SJ, Davis GL, Weiss JA.

J Orthop Res. 2013 Aug;31(8):1226-33. doi: 10.1002/jor.22352. Epub 2013 Mar 28.


Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.

O'Leary JG, McKenna GJ, Klintmalm GB, Davis GL.

Liver Transpl. 2013 Apr;19(4):463-5. doi: 10.1002/lt.23623. No abstract available.


Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation.

Kim PT, Onaca N, Chinnakotla S, Davis GL, Jennings LW, McKenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB.

Clin Transplant. 2013 Mar-Apr;27(2):311-8. doi: 10.1111/ctr.12089. Epub 2013 Jan 28.


Use of protease inhibitors in liver transplant recipients.

Davis GL, O'Leary JG.

Gastroenterol Hepatol (N Y). 2012 Mar;8(3):183-4. No abstract available.


Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined.

O'Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB.

Transpl Int. 2012 Aug;25(8):825-9. doi: 10.1111/j.1432-2277.2012.01498.x. Epub 2012 May 30.


Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.

O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM.

Liver Transpl. 2012 Aug;18(8):949-54. doi: 10.1002/lt.23439.


Demographics of hepatitis C virus today.

Gonzalez SA, Davis GL.

Clin Liver Dis (Hoboken). 2012 Mar 6;1(1):2-5. doi: 10.1002/cld.3. eCollection 2012 Feb. Review. No abstract available.


Economic model of a birth cohort screening program for hepatitis C virus.

McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC.

Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.


Clinical vignettes in geriatric depression.

Spoelhof GD, Davis GL, Licari A.

Am Fam Physician. 2011 Nov 15;84(10):1149-54.


Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression.

McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri M, O'Leary JG, Davis GL, Levy MF, Goldstein RM, Klintmalm GB.

Am J Transplant. 2011 Nov;11(11):2379-87. doi: 10.1111/j.1600-6143.2011.03767.x. Epub 2011 Oct 3.


A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.

Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG.

Liver Transpl. 2011 Dec;17(12):1394-403. doi: 10.1002/lt.22417.


Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation.

O'Leary JG, Trotter JF, Neri MA, Jennings LW, McKenna GJ, Davis GL, Klintmalm GB.

Proc (Bayl Univ Med Cent). 2011 Jul;24(3):187-91.


High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.

O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, Klintmalm GB, Terasaki PI.

Am J Transplant. 2011 Sep;11(9):1868-76. doi: 10.1111/j.1600-6143.2011.03593.x. Epub 2011 Jun 14.


Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology.

Chinnakotla S, Klintmalm GB, Kim P, Tomiyama K, Klintmalm E, Davis GL, Trotter JF, Saad R, Landaverde C, Levy MF, Goldstein RM, Stone MJ.

Transplantation. 2011 Aug 15;92(3):341-5. doi: 10.1097/TP.0b013e3182247b05.


Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.

O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL.

Clin Gastroenterol Hepatol. 2011 Aug;9(8):700-704.e1. doi: 10.1016/j.cgh.2011.04.007. Epub 2011 Apr 15.


Hepatitis C virus replication and potential targets for direct-acting agents.

O'Leary JG, Davis GL.

Therap Adv Gastroenterol. 2010 Jan;3(1):43-53. doi: 10.1177/1756283X09353353.


Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.

Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C.

Clin Gastroenterol Hepatol. 2010 Nov;8(11):924-33; quiz e117. doi: 10.1016/j.cgh.2010.06.032. Epub 2010 Aug 14. Review.


Portable, battery-operated, low-cost, bright field and fluorescence microscope.

Miller AR, Davis GL, Oden ZM, Razavi MR, Fateh A, Ghazanfari M, Abdolrahimi F, Poorazar S, Sakhaie F, Olsen RJ, Bahrmand AR, Pierce MC, Graviss EA, Richards-Kortum R.

PLoS One. 2010 Aug 4;5(8):e11890. doi: 10.1371/journal.pone.0011890.


The healthcare burden imposed by liver disease in aging Baby Boomers.

Davis GL, Roberts WL.

Curr Gastroenterol Rep. 2010 Feb;12(1):1-6. doi: 10.1007/s11894-009-0087-2.


Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.

Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL.

Liver Transpl. 2010 Apr;16(4):431-9. doi: 10.1002/lt.22004.


Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.

Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, Macdiarmid SA.

J Urol. 2010 Apr;183(4):1438-43. doi: 10.1016/j.juro.2009.12.036. Epub 2010 Feb 20.


Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation.

Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, Onaca N, Goldstein R, Levy M, Klintmalm GB.

Liver Transpl. 2009 Dec;15(12):1834-42. doi: 10.1002/lt.21953.


Inferior vena cava stent resolves hepatopulmonary syndrome in an adult with a spontaneous inferior vena cava-portal vein shunt.

O'Leary JG, Rees CR, Klintmalm GB, Davis GL.

Liver Transpl. 2009 Dec;15(12):1897-900. doi: 10.1002/lt.21884. No abstract available.


Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW.

Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6. doi: 10.1053/j.gastro.2009.09.067. Epub 2009 Oct 25.


Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease.

O'Leary JG, Davis GL.

Liver Transpl. 2009 Oct;15(10):1325-9. doi: 10.1002/lt.21836.


Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation.

Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB.

Liver Transpl. 2009 Jun;15(6):574-80. doi: 10.1002/lt.21738.


Post-liver transplant survival in hepatitis C patients is improving over time.

O'Leary JG, Randall H, Onaca N, Jennings L, Klintmalm GB, Davis GL.

Liver Transpl. 2009 Apr;15(4):360-8. doi: 10.1002/lt.21691.


Hepatitis C virus: a critical appraisal of approaches to therapy.

Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N.

Clin Gastroenterol Hepatol. 2009 Apr;7(4):397-414; quiz 366. doi: 10.1016/j.cgh.2008.11.016. Epub 2008 Nov 21. Review. No abstract available.


Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.

Nelson DR, Rustgi V, Balan V, Sulkowski MS, Davis GL, Muir AJ, Lambiase LR, Dickson RC, Weisner RH, Fiscella M, Cronin PW, Pulkstenis E, McHutchison JG, Subramanian GM.

Clin Gastroenterol Hepatol. 2009 Feb;7(2):212-8. doi: 10.1016/j.cgh.2008.10.035. Epub 2008 Nov 7.


A multi-state Salmonella Typhimurium outbreak associated with frozen vacuum-packed rodents used to feed snakes.

Fuller CC, Jawahir SL, Leano FT, Bidol SA, Signs K, Davis C, Holmes Y, Morgan J, Teltow G, Jones B, Sexton RB, Davis GL, Braden CR, Patel NJ, Deasy MP 3rd, Smith KE.

Zoonoses Public Health. 2008 Oct;55(8-10):481-7.


Future trends in hepatology: challenges and opportunities.

Rustgi VK, Davis GL, Herrine SK, McCullough AJ, Friedman SL, Gores GJ.

Hepatology. 2008 Aug;48(2):655-61. doi: 10.1002/hep.22451. No abstract available. Erratum in: Hepatology.2008 Oct;48(4):1356.


Hepatocellular carcinoma: management of an increasingly common problem.

Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM.

Proc (Bayl Univ Med Cent). 2008 Jul;21(3):266-80.


Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis.

Parsi MA, Saadeh SN, Zein NN, Davis GL, Lopez R, Boone J, Lepe MR, Guo L, Ashfaq M, Klintmalm G, McCullough AJ.

Gastroenterology. 2008 Sep;135(3):803-7. doi: 10.1053/j.gastro.2008.05.045. Epub 2008 May 21.


Indications for liver transplantation.

O'Leary JG, Lepe R, Davis GL.

Gastroenterology. 2008 May;134(6):1764-76. doi: 10.1053/j.gastro.2008.02.028. Review.


Supplemental Content

Loading ...
Support Center